Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS inhibitors may prevent colorectal cancer metachronous metastasis by suppressing TGF‑β mediated epithelial‑mesenchymal transition.

Molecular medicine reports - 1 Jan 2025

Guo Yaoyu, Hu Chuling, Cai Kuntai, Long Guojie, Cai Du, Yu Zhaoliang, Huang Xinxin, Cai Zerong, Hu Peishan, Chen Yufeng, Gao Feng, Wu Xiaojian

Abstract excerpt

In colorectal cancer (CRC), KRAS mutations enhance metachronous metastasis, a condition without prognostic biomarkers or preventive measures. The present study demonstrated that KRAS mutation may be a risk factor for CRC metachronous metastasis through meta‑analysis of public databases. A risk scoring model was constructed using machine learning for predicting metachronous metastasis in KRAS‑mutant CRC. Wound...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Cell Movement

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Epithelial-Mesenchymal Transition

Share to Gene Expression Regulation, Neoplastic

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins p21(ras)

Share to Transforming Growth Factor beta

Source

Open in PubMed Open full text

Identifiers

PMID: 39540351
DOI: 10.3892/mmr.2024.13389
PMCID: PMC11576929

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS inhibitors may prevent colorectal cancer metachronous metastasis by suppressing TGF‑β mediated epithelial‑mesenchymal transition.PMID 39540351Read ↗

KRAS Inhibitors Are Potential Prophylaxis for Colorectal Cancer Metachronous MetastasisSemantic proximity Read ↗

Prognostic value of KRAS mutation in patients undergoing pulmonary metastasectomy for colorectal cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

Oncogenic Kras drives invasion and maintains metastases in colorectal cancer.Semantic proximity Read ↗

SLC14A1 and TGF-β signaling: a feedback loop driving EMT and colorectal cancer metachronous liver metastasisSemantic proximity Read ↗

Combined Mutation of Apc, Kras, and Tgfbr2 Effectively Drives Metastasis of Intestinal Cancer.Semantic proximity Read ↗

Mutation Status of RAS, TP53 , and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver MetastasesSemantic proximity Read ↗

Mutations of key driver genes in colorectal cancer progression and metastasis.Semantic proximity Read ↗

Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements.Semantic proximity Read ↗

The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer.Semantic proximity Read ↗

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer.Semantic proximity Read ↗

KRAS and BRAF Mutations as survival prognostic factors for Metastatic Colorectal Cancer patients after Lung metastasectomy: A Systematic Review and Meta-AnalysisSemantic proximity Read ↗

Loss of Smad4 expression predicts liver metastasis in human colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.